Enfermedades producidas por micobacterias ambientales

Medicina Clinica

Volumn 113, Issue 16, 1999, Pages 621-630

  Medina Cruz, María Victoria ^a   Sauret Valet, Jesús ^b   Caminero Luna, José A ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIMYCOBACTERIAL AGENT; CLARITHROMYCIN; CLOFAZIMINE; ETHIONAMIDE; IMIPENEM; ISONIAZID; QUINOLONE DERIVATIVE; STREPTOMYCIN; SULFAMETHOXAZOLE; TOBRAMYCIN;

DISEASE TRANSMISSION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; REVIEW; SYMPTOMATOLOGY;

ENVIRONMENT; HUMANS; MYCOBACTERIUM INFECTIONS; RISK FACTORS;

EID: 0040883241     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Raviglione M, Snider D, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
2. World Health Organization. Tuberculosis Programme. WHO report on the tuberculosis epidemic, 1994. Ginebra: World Health Organization, 1994.
3. Caminero JA. Medidas básicas para el control de la tuberculosis en una comunidad. Med Clin (Barc) 1994; 102: 67-73.
4. Timpe A, Runyon EH. The relationship of «atypical» acid-fast bacteria to human disease. A preliminary report. J Lab Clin Med 1954, 44: 202-209.
5. Ruiz Manzano J, Manterola JM, Ausina V, Sauret J. Nomenclature y clasificación de las micobacterias. Arch Bronconeumol 1998; 34: 154-157
6. Yates MD, Pozniak A, Uttley AH, Clarke R, Grange JM. Isolation of environmental mycobacteria from clinical specimens in South-East England: 1973-1993. Int J Tuberc Lung Dis 1997; 1: 75-80.
7. Horsburgh CR Jr, Schoenfelder JR, Gordin FM, Cohn DL, Sullam PM, Wynne BA. Geographic and seasonal variation in Mycobacterium avium bacteremia among North American patients with AIDS. Am J Med Sci 1997; 313: 341-345.
8. Lewis AG, Lasche EM, Armstrom AL, Dunba FP. A clinical study of lung disease due non photochromogenic acid-fast bacilli. Ann Intern Med 1960; 53: 273-285.
9. Christianson LC, Dewlett HJ. Pulmonary disease in adults associated with unclassified mycobacteria. Am Lung Med 1960; 29: 980-991.
10. Good RC, Snider DE. Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis 1982; 146: 829-833.
11. Contreras MA, Cheung OT, Sanders DE, Goldstein RS. Pulmonary infection with nontuberculous mycobacteria. Am Rev Respir Dis 1988; 137: 149-152.
12. Wickman K. Clinical significance of nontuberculous mycobacteria: a bacteriological survey of Swedish strains isolated between 1973 and 1981. Scand J Infect Dis 1986; 18: 337-345.
13. Paul A. An environmental study of the opportunist mycobacteria. Med Lab Tech 1973; 30: 11-19.
14. Chakrabarti A, Sharma M, Dubey ML. Isolation rates of different mycobacterial species from Chandigarh (north India). Indian J Med Respir 1990; 91: 111-114.
15. Zaman R. Tuberculosis in Saudi Arabia: epidemiology and incidence of Mycobacterium tuberculosis and other mycobacterial species. Tubercle 1991; 72: 43-49.
16. Fernández-Flix S, Sauret J, Ausina V, Condom MJ, Rodríguez-Froján G, Luquin M et al. Enfermedad pulmonar por micobacterias ambientales oportunistas. Revisión de 5 casos. Med Clin (Barc) 1990; 95: 53-56.
17. Martínez Moragón E, Menéndez R, Santos M, Lorente R, Marco V. Enfermedad pulmonar por micobacterias ambientales oportunistas en pacientes sin infección por el virus de la inmunodeficiencia humana. Factores de riesgo, clinica, diagnóstico y evolución. Arch Bronconeumol 1996; 32: 170-175.
18. O'Brien RJ, Geiter LJ, Snider DE. The epidemiology of nontuberculous mycobacterial diseases in the United States. Result from a national survey. Am Rev Respir Dis 1987; 135: 1.007-1.014.
19. Fergie JE, Milligan TW, Henderson BM, Stafford WW. Intrathoracic Mycobacterium avium complex infection in immunocompetent children: case report and review. Clin Infect Dis 1997; 24: 250-253.
20. Jiva TM, Jacoby HM, Weymouth LA, Kaminski DA, Portmore AC. Mycobacterium xenopi: innocent by stander or emerging pathogen? Clin Infect Dis 1997; 24: 226-232.
21. Lind A, Larsson LO, Bentzon MW, Magnusson M, Olofson J, Sjogren I et al. Sensitivity to sensitins and tuberculin in Swedish children. I. A study of schoolchildren in an urban area. Tubercle 1991; 72: 29-36.
22. De March Ayuela P. Micobacterias no tuberculosas en Barcelona. Sensibilizaciones comparativas entre tuberculina RT-23 con sensitinas de Mycobacterium avium y Mycobacterium scrofulaceum. Rev Clin Esp 1985; 175: 141-147.
23. Hoover DR, Saah AJ, Bachellar H, Phair J, Detels R, Anderson R et al. Clinical manifestations of AIDS in the era of Pneumocystis profilaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993; 329: 1.922-1.926.
24. Daniel P, Chin MD, Philip MPH, Hopewell MD. Mycobacterial complications of HIV infection. Clin Chest Med 1996; 17: 697-711.
25. Okello DO, Sewakambo N, Goodgame R, Aisu TO, Kwezi M, Morrissey A. Absence of bacteremia with Mycobacterium avium intracellulare in Ugandan patients with AIDS. J Infect Dis 1990; 62: 208.
26. Von Reyn CF, Maslow JN, Barber TW, Falkinhan III JO, Arbeit RD. Persistent colonization of potable water as a source of Mycobacterium avium infection in AIDS. Lancet 1994; 343: 1.137-1.141.
27. Collins CH, Grange JM, Noble WC, Yates MD. Mycobacterium marinum infections in man. J Hyg Camb 1985; 94: 135-149.
28. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis 1992; 15: 1-10.
29. French AL, Senator DA, Gordin FM. Nontuberculous Mycobacterial infections. Med Clin North Am 1997; 81: 361-379.
30. Robert Horsburgh C Jr. Mycobacterium avium complex infection in the Acquired Immunodeficiency Syndrome. N Engl J Med 1991; 324: 1.332-1.338.
31. Robert Horsburgh C Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139: 4-7.
32. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119: 107-159.
33. Moore EH. Atypical mycobacterial infection in the lung: CT appearance. Radiology 1993; 187: 777-782.
34. Epstein MD, Aranda CP, Bonk S, Hanna B, Rom WN. The significance of Mycobacterium avium complex cultivation in the sputum of patients with pulmonary tuberculosis. Chest 1997; 111: 142-147.
35. Caminero JA, Medina MV, Rodriguez de Castro F, Cabrera P. Tuberculosis y otras micobacteriosis. En: Caminero JA, Fernández Fau L, editores. Manual de neumologia y cirugía torácica. Madrid: Editores Médicos S.A., 1998; 83: 1.389-1.419.
36. Fishman JE, Schwartz DS, Sais GJ. Mycobacterium kansasii pulmonary infection in patients with AIDS: spectrum of chest radiographic findings. Radiology 1997; 204: 171-175.
37. Hartman TE, Swensen SJ, Williams DE. Mycobacterium avium intracellulare complex: evaluation with CT. Radiology 1993; 187: 23-26.
38. Tanaka E, Amitani R, Niimi A, Suzuki K, Murayama T, Kuze F. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1997; 155: 2.041-2.046.
39. Von Reyn CF, Green PA, McCormick D, Huitt GA, Marsh BJ, Magnusson M et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative: an open study of patients with M. avium complex infection or tuberculosis. Clin Infect Dis 1994; 19: 15-20.
40. Horsburgh CR Jr, Mason UG, Farhi DC, Iseman MD. Disseminated infection with Mycobacterium avium intracellulare. Medicine (Baltimore) 1985; 64: 36-48.
41. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1997; 156 (Supl): 1-25.
42. Lincoln EM, Gilbert LA. Disease in children due to mycobacteria other than Mycobacterium tuberculosis. Am Rev Respir Dis 1972; 105: 683-714.
43. Lai KK, Stottmeier KD, Sherman IH, McCabe WR. Mycobacterial cervical lymphadenopathy. JAMA 1984; 251: 1.286-1.288.
44. Zaugg M, Salfinger M, Opravil M, Lüthy R. Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review. Clin Infect Dis 1993; 16: 540-549.
45. Rodríguez de Castro F, Caminero JA, Juliá G, Cabrera P. Transcarinal needle aspiration in the diagnosis of mediastinal adenitis in a patient infected with the human immunodeficiency virus. Thorax 1991; 46: 75.
46. Hoffman PC, Fraser DW, Robicsek F, O'Bar PR, Mauney CU. Two outbreaks of sternal wound infections due to organism of Mycobacterium fortuitum complex. J Infect Dis 1981; 143: 533-542.
47. Wenger JD, Spika JS, Smithwick RW, Pryor V, Dodson DW, Carden GA et al. Outbreak of Mycobacterium chelonae infection associated with use of jet injectors. JAMA 1990; 264: 373-376.
48. Costrini AM, Mahler DA, Gross WM, Hawkins JE, Yesner R, D'Esopo ND. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis 1981; 123: 104-109.
49. Campo RE, Campo CE. Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24: 1.233-1.238.
50. Tortoli E, Cichero P, Chirillo MG, Gismondo MR, Bono L, Gesu G et al. Multicenter comparison of ESP culture system II with BACTEC 460TB and with Löwenstein-Jensen medium for recovery of mycobacteria from different clinical specimens, including blood. J Clin Microbiol 1998; 36: 1.378-1.381.
51. Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother 1988; 32: 1.131-1.136.
52. Ahn CH, Wallace RJ Jr, Steele LC, Murphy DT. Sulfonamide containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am Rev Respir Dis 1987; 135: 10-16.
53. Wallace JR Jr, Dunbar D, Brown BA, Onyi G, Dunlap R, Ahn CH et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994; 18: 736-743.
54. Chapman JS. The atypical mycobacteria. Am Rev Respir Dis 1982; 125 (Supl): 119-124.
55. Chiu J, Nussbaum J, Bozzette S, Tilles J, Young LS, Leedom J et al. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacine, ethambutol, rifampin and ciprofloxacin. Ann Intern Med 1990; 113: 358-361.
56. Dautzenberg B, Saint Marc T, Meyohas MC, Eliaszewitch M, Haniez F, Rogues MA et al. Clarithromycin an other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired inmunodeficiency syndrome. Arch Intern Med 1993; 153: 368-372.
57. Young LS, Wiviott L, Wu M, Kolonosky P, Bolan R, Inderlied CB. Azitromycin for treatment on Mycobacterium intracellulare complex infection in patients with AIDS. Lancet 1991; 338: 1.107-1.109.
58. Alangaden GJ, Lerner SA. The clinical use of fluorquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25: 1.213-1.221.
59. Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A et al. Activity of clarithromycin against Mycobacterium avium infection in patients with acquired inmune deficiency syndrome. Am Rev Respir Dis 1991; 144: 564-559.
60. Sullam PM. Rifabutin therapy for disseminated Mycobacteriurn avium complex infection. Clin Infect Dis 1996; 22 (Supl): 37-42.
61. Shafran SD, Singer J, Zarowny DP, Philips P, Salit I, Walmsley SL et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteriemia AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine and ciprofloxacin. N Engl J Med 1996; 335: 377-383.
62. Centers for Disease Control. Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR 1996; 45: 921-925.
63. Siegal EP. Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS. Clin Infect Dis 1996; 22 (Supl 1): 23-32.
64. Nichols ChW. Mycobacterium avium complex infection, rifabutin, and uveitis: is there a connection? Clin Infect Dis 1996; 22 (Supl 1): 43-49.
65. Pierce M, Crampton S, Henry D, Heifits L, LaMarca A, Montecalvo M et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-391.
66. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. N Engl J Med 1993; 329: 898-904.
67. Horsburgh RC Jr. Advances in the prevention and treatment of Mycobacterium avium disease. N Engl J Med 1996; 335: 428-429.
68. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease. Am Rev Respir Dis 1991; 143: 1.381-1.385.
69. Wallace RJ Jr, Brown BA, Griffith DE, Girard WE, Murphy DT. Clarithromycine regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996; 153: 1.766-1.772.
70. Dautzenberg B, Piperno D, Diot P, Truffot C, Pernot J, Chauvin P and the Clarithromycine Study Group of France. Clarithromycine in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995; 107: 1.035-1.040.
71. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1990; 142: 940-953.
72. Pomerantz M, Madsen L, Goble M, Iseman MD. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991; 52: 1.108-1.112.
73. Schaad UB, Votteler TP, H. McCracken GN, Nelson JD. Management of atypical mycobacterial lymphadenitis in childhood: a review based on 380 cases. J Pediatr 1979; 95: 356-360.
74. Pezzia W, Raleigh JW, Bailey MC, Toth EA, Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981; 3: 1.035-1.039.
75. Ahn CH, Lowell JR, Ahn SS, Ahn SI, Hurst GU. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983; 128: 1.048-1.050.
76. Harris GD, Johanson WG Jr, Nicholson DP. Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii Am Rev Respir Dis 1975; 112: 31-36.
77. Jenkins PA, Banks J, Campbell IA, Smith NP. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Thorax 1994; 49: 442-445.
78. Sauret J, Hernández Flix S, Castro E, Hernández L, Ausina V, Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months chemotherapy. Tuber Lung Dis 1995; 76: 104-108.
79. Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility testing of 5 subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28: 807-811.
80. Brown BA, Wallace RJ Jr, Onyi GO, De Rosa V, Wallace III RJ. Activities of four macrolides, including clarithromycine, againts Mycobacterium fortuitum, Mycobacterium chelonae-like organisms. Antimicrob Agents Chemother 1992; 36: 180-184.
81. Edelstein H. Mycobacterium marinum skin infections. Arch Intern Med 1994; 154: 1.359-1.364.
82. Banks J, Jenkins PA, Smith AP. Pulmonary infection with Mycobacterium malmoense: a review of treatment and response. Tubercle 1985; 66: 197-203.
83. Bell RC, Higuchi JH, Donovan WN, Drasnow I, Johanson WG. Mycobacterium simiae: clinical features and follow up of twenty four patients. Am Rev Respir Dis 1983; 127: 35-38.
84. Banks J, Jenkins PA. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non tuberculous mycobacteria. Thorax 1987; 42: 838-842.